Claudia Guida

ORCID: 0000-0001-9475-1064
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic function and diabetes
  • Diabetes Treatment and Management
  • Iron Metabolism and Disorders
  • Receptor Mechanisms and Signaling
  • Diet and metabolism studies
  • Hemoglobinopathies and Related Disorders
  • Diabetes and associated disorders
  • Diabetes Management and Research
  • Bariatric Surgery and Outcomes
  • Cellular transport and secretion
  • Neuropeptides and Animal Physiology
  • Erythrocyte Function and Pathophysiology
  • Neuroendocrine Tumor Research Advances
  • Genetics and Physical Performance
  • Neonatal and fetal brain pathology
  • Historical and Environmental Studies
  • Photosynthetic Processes and Mechanisms
  • Regulation of Appetite and Obesity
  • Thermal Regulation in Medicine
  • Microtubule and mitosis dynamics
  • Lysosomal Storage Disorders Research
  • RNA modifications and cancer
  • Optimism, Hope, and Well-being
  • CRISPR and Genetic Engineering
  • Diverse academic and cultural studies

University of Oxford
2017-2024

Oxford Centre for Diabetes, Endocrinology and Metabolism
2017-2024

Churchill Hospital
2017-2023

University of Catania
2021

Heidelberg University
2014-2019

University Hospital Heidelberg
2019

European Molecular Biology Laboratory
2014-2019

European Institute of Oncology
2011

By restoring glucose-regulated insulin secretion, glucagon-like peptide-1–based (GLP-1–based) therapies are becoming increasingly important in diabetes care. Normally, the incretins GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) jointly maintain normal blood glucose levels by stimulation of secretion pancreatic β cells. However, reason why only GLP-1–based drugs effective improving after presentation has not been resolved. ATP-sensitive K+ (KATP) channels play a crucial role...

10.1172/jci140046 article EN Journal of Clinical Investigation 2020-11-15

Abstract Aims/hypothesis Diabetes mellitus is associated with impaired insulin secretion, often aggravated by oversecretion of glucagon. Therapeutic interventions should ideally correct both defects. Glucagon-like peptide 1 (GLP-1) has this capability but exactly how it exerts its glucagonostatic effect remains obscure. Following release GLP-1 rapidly degraded from GLP-1(7–36) to GLP-1(9–36). We hypothesised that the metabolite GLP-1(9–36) (previously believed be biologically inactive) a...

10.1007/s00125-023-06060-w article EN cc-by Diabetologia 2023-12-21

Aims The gut hormone peptide tyrosine (PYY) is critical for maintaining islet integrity and restoring function following Roux‐en‐Y gastric bypass (RYGB). expression of PYY its receptors (NPYRs) in islets has been documented but not fully characterized. Modulation by the proteolytic enzyme dipeptidyl peptidase IV (DPP‐IV) investigated impact DPP‐IV inhibition on remains unexplored. Here we have addressed these gaps their effects glucose‐stimulated insulin secretion (GSIS). We also changes...

10.1111/dom.13113 article EN cc-by-nc Diabetes Obesity and Metabolism 2017-09-11

Summary The incretin hormone glucagon-like peptide 1(7-36) (GLP-1(7-36)) stimulates insulin and inhibits glucagon secretion. mechanisms by which GLP-1 suppresses release are unclear as glucagon-secreting α-cells express receptors (GLP-1Rs) at very low levels. Here, we examine the underlying mechanisms. We find that both GLP-1(7-36) its degradation product GLP-1(9-36) inhibit secretion physiological (pM) concentrations. Whereas effect of is sensitive to PKA inhibition, exerts a...

10.1101/785667 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2019-09-30

Mus musculus BL6 strains, specifically C57BL/6N and C57BL/6J, are frequently analyzed in an interchangeable manner as ‘wildtype’ controls without indication of the substrain. We hematological iron-related parameters C57BL/6J mice show differences hematocrit, mean corpuscular volume well non-heme iron content spleen, which was significantly higher compared to At molecular level, elevated splenic levels were associated with ferritin (FTL FTH) lower transferrin receptor 1 (TfR1) protein levels....

10.1097/hs9.0000000000000304 article EN cc-by-nc-nd HemaSphere 2019-11-09

Mucopolysaccharidosis III (Sanfilippo syndromes) types A–D are rare lysosomal storage disorders characterized by heparan sulfate accumulation and neurodegeneration. Patients with MPS present developmental stagnation and/or regression, sleep disturbance, behavioral abnormalities usually in the first years of life. Epilepsy may occur a proportion patients during disease course. However, progression epilepsy EEG changes have not been systematically investigated. We report electroclinical...

10.3389/fneur.2021.705423 article EN cc-by Frontiers in Neurology 2021-07-19

The thesis is the renewed relationship between man and environment highlights need for a new conception of urban territory Government establishment sustainable cities. Cities are real engines regional development national and, in recent years, have become focus attention Community policies that consider completely different innovative than before.

10.6092/unina/fedoa/8053 article EN 2010-11-28
Coming Soon ...